Selvita SA SLV
GPW · Poland · Health Technology
PLN 21.35-0.85 (-3.83%)
Market closed· · PLN · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · PLN · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Selvita S.A. (WSE: SLV), one of the leading Drug Discovery and Development organizations in Europe, has published its financial results for Q1 2026 and latest backlog. The Company has decided to launch a strategic options review for the Group's further development and to maximize long-term shareholder value.
As European markets navigate the complexities of Middle East tensions and energy market volatility, the pan-European STOXX Europe 600 Index has shown resilience, ending a recent week with a notable gain of 3.92%. Amid these fluctuations, investors may find opportunities in stocks that appear to be trading below their estimated value, particularly as inflationary pressures and economic forecasts continue to shape the investment landscape. Identifying potentially undervalued stocks often...
As the European markets experience a positive shift, with the STOXX Europe 600 Index climbing 3.92% amid hopes for a shorter Middle East conflict, investors are keenly observing opportunities that may arise from current economic conditions such as rising energy costs and inflation pressures. In this context, identifying undervalued stocks becomes crucial, as these equities might offer potential value when aligned with market trends and economic indicators.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.